We don’t know if the copy is going to be in the paper or just online, but today, Stat makes its debut — in both formats. The site promises “Reporting from the frontiers of health and medicine We take you inside the science labs and hospitals, biotech boardrooms and political backrooms. We dissect crucial discoveries. We examine controversies and puncture hype. We hold individuals and institutions accountable. We introduce you to the power brokers and personalities who are driving a revolution in human health.
Today’s story –how social media is gumming up clinical trials and riling up pharma investors. It begins with a story of a woman who posts about being in a clinical trial.
The stock of a Cambridge-based biotech company would rise and fall with her updates. Investors would scrutinize Stracham’s words and pore over individual frames in her videos. Stracham herself would be subjected to…
View original post 293 more words